Genedrive supplies CYP2C19 point-of-care testing to LNWH
- London North West University Healthcare NHS Trust
- London
- Below threshold - without competition
- 1 December 2026 to 30 November 2027
London North West University Healthcare NHS Trust is buying a point-of-care genetic testing service from Genedrive Diagnostics Ltd.
The test will quickly identify CYP2C19 variants linked to changes in how patients metabolise and respond to clopidogrel.
The trust awarded the £57,871 contract directly, without competition, in November 2026. It is due to end in November 2027.
Contract ends November 2027
- What
- Point-of-care testing analysers and rapid tests
- Supplier
- Genedrive Diagnostics Ltd
- Value
- £57,871
- How it was bought
- Below threshold - without competition
- Dates and next
- Dec 2026 to Nov 2027